A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants
oleh: Denise Haslwanter, M. Eugenia Dieterle, Anna Z. Wec, Cecilia M. O’Brien, Mrunal Sakharkar, Catalina Florez, Karen Tong, C. Garrett Rappazzo, Gorka Lasso, Olivia Vergnolle, Ariel S. Wirchnianski, Robert H. Bortz, Ethan Laudermilch, J. Maximilian Fels, Amanda Mengotto, Ryan J. Malonis, George I. Georgiev, Jose A. Quiroz, Daniel Wrapp, Nianshuang Wang, Kathryn E. Dye, Jason Barnhill, John M. Dye, Jason S. McLellan, Johanna P. Daily, Jonathan R. Lai, Andrew S. Herbert, Laura M. Walker, Kartik Chandran, Rohit K. Jangra
| Format: | Article |
|---|---|
| Diterbitkan: | American Society for Microbiology 2021-10-01 |
Deskripsi
The U.S. FDA has issued emergency use authorizations (EUAs) for multiple investigational monoclonal antibody (MAb) therapies for the treatment of mild to moderate COVID-19.